Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $225000.0.

  • Assembly Biosciences' Gains from Investment Securities changed N/A to $225000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $225000.0, marking a year-over-year decrease of 9190.36%. This contributed to the annual value of $2.0 million for FY2024, which is 1949.22% down from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Gains from Investment Securities is $225000.0.
  • Assembly Biosciences' 5-year Gains from Investment Securities high stood at $2.8 million for Q4 2023, and its period low was -$2.8 million during Q3 2021.
  • Its 5-year average for Gains from Investment Securities is -$46071.4, with a median of -$8000.0 in 2021.
  • Per our database at Business Quant, Assembly Biosciences' Gains from Investment Securities crashed by 205000.0% in 2022 and then skyrocketed by 38213.2% in 2023.
  • Assembly Biosciences' Gains from Investment Securities (Quarter) stood at -$219000.0 in 2021, then crashed by 349.77% to -$985000.0 in 2022, then skyrocketed by 382.13% to $2.8 million in 2023, then dropped by 29.26% to $2.0 million in 2024, then crashed by 88.56% to $225000.0 in 2025.
  • Its Gains from Investment Securities stands at $225000.0 for Q3 2025, versus $225000.0 for Q2 2025 and $2.0 million for Q4 2024.